About ICRF
 
Israel Cancer Research Fund (ICRF) is the largest organization in North America solely devoted to supporting cancer research in Israel. ICRF has provided more than 2,300 grants and approximately $64 million to outstanding cancer researchers at every major institution in Israel. It is alongside the hard work of ICRF-funded scientists that cancer drugs such as Gleevac®, Doxil®, and Velcade® were developed and are being used to treat hundreds of thousands of cancer patients worldwide annually. ICRF changes the lives of cancer patients, survivors and their families.
 
ICRF is Unique Among Non-Profits that Fund Scientific and Medical Research in Israel in the following ways:
  • 100% of an ICRF grant goes directly to research
  • ICRF funds individual scientists, rather than "bricks and mortar."
  • ICRF is "institution-neutral." Our funding goes to scientists at all of Israel's top biomedical research centers.
  • ICRF awards are made solely on the basis of scientific merit and the ability of the individual scientist to make a significant impact in his/her field.
  • ICRF grants to young Israeli scientists are often the first grants these scientists receive after completing their academic training. It is these grants that allow many of these young Israeli scientists to begin their professional careers in Israel.
  • ICRF grants fund basic and clinical research that can have dramatic, global impact. Discoveries made by ICRF-funded scientists have led to major advances in the understanding and treatment of cancer.
     
Significant accomplishments by ICRF funded scientists include:
  • Awarded Israel's first two Nobel Prizes in the sciences (2004 Nobel Laureates in Chemistry, Prof. Avram Hershko and Prof. Aaron Ciechanover) for the discovery of the ubiquitin system. This led to the discovery of the life-saving multiple myeloma drug Velcade®.
  • Demonstrated that the p53 gene acts as a tumor suppressor -- one of the hallmark discoveries in cancer in the 20th Century.
  • Identified the structure of the Philadelphia Chromosome, the first genetic linkage identified in leukemia, leading to the development of Gleevec®, one of the first targeted cancer therapies. Over 300,000 leukemia patients a year take Gleevec® to extend and enhance their lives.
  • Developed the cancer drug Doxil®, for ovarian, breast and AIDS-related cancers
For more information on ICRF please visit us online at http://www.icrfonline.org/
Administrative Login   Play Ads Full Screen With Controls
Powered by Wizadjournal - Developed by PBCS Technology
Servers: web1 mysql3 Event: 1254